Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inolas
- Development stage
- Phase 3
- Lead developer
- Otsuka Pharmaceutical
- Administration
- Oral
01
Overview
**Inolas** is a Japanese prescription, semi-digested polymeric enteral nutrition formula developed by EN Otsuka Pharmaceutical for nutritional support in people unable to maintain adequate oral intake, including patients requiring tube feeding. Developed as EN-P05, it is a high-calorie, high-protein liquid formulation providing 1.6 kcal/mL, 6.40 g protein per 100 mL, and essential vitamins and trace elements; it is administered orally or through an enteral feeding tube. It was approved in Japan for nutritional maintenance after surgery, particularly when long-term oral food intake is difficult. ([pmda.go.jp](https://www.pmda.go.jp/drugs/2019/P20190412002/130589000_23100AMX00279_A100_1.pdf))
- Brand names
- Inolas
- Other names
- Inolas combination enteral liquidイノラス配合経腸用液
Beyond the preview
Go deeper on Inolas.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inolas.